CENTRAL TRUST Co Has $5.52 Million Position in Gilead Sciences, Inc. (GILD)
CENTRAL TRUST Co trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,968 shares of the biopharmaceutical company’s stock after selling 8,939 shares during the period. CENTRAL TRUST Co’s holdings in Gilead Sciences were worth $5,519,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the stock. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 583.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares during the period. Dubuque Bank & Trust Co. boosted its holdings in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 267 shares in the last quarter. Penserra Capital Management LLC boosted its holdings in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares in the last quarter. Webster Bank N. A. boosted its holdings in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 624 shares in the last quarter. Finally, American Beacon Advisors Inc. purchased a new stake in shares of Gilead Sciences in the first quarter valued at about $143,000. Hedge funds and other institutional investors own 73.99% of the company’s stock.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. Insiders sold 388,486 shares of company stock valued at $31,178,297 over the last three months. 1.30% of the stock is owned by insiders.
A number of equities research analysts have weighed in on the company. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Thursday, August 31st. Deutsche Bank AG reissued a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Credit Suisse Group reissued an “outperform” rating and set a $85.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price target for the company in a report on Monday, June 26th. Eleven analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $84.29.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 1.84% during mid-day trading on Monday, hitting $82.51. 5,058,493 shares of the stock traded hands. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a market cap of $107.75 billion, a price-to-earnings ratio of 8.96 and a beta of 1.14. The stock has a 50-day moving average of $77.54 and a 200-day moving average of $70.38.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.08 EPS. Analysts anticipate that Gilead Sciences, Inc. will post $8.78 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
ILLEGAL ACTIVITY WARNING: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/02/central-trust-co-has-5-52-million-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.